Pentoxifylline improves nonalcoholic steatohepatitis: A randomized placebo-controlled trial
نویسندگان
چکیده
منابع مشابه
effects of pentoxifylline on non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled trial in iran
conclusions decreases in the serum levels of liver aminotransferases and cytokines, in both groups, are related to low-calorie diets and exercise, rather than ptx. results the serum levels of liver aminotransferases were significantly reduced at 3 months and at 6 months, compared with baseline, in both groups. the serum levels of il-6 were significantly decreased, in both groups, only at 6 mont...
متن کاملEffects of Pentoxifylline on Non-Alcoholic Steatohepatitis: A Randomized, Double-Blind, Placebo-Controlled Trial in Iran
BACKGROUND Non-alcoholic steatohepatitis (NASH) is a progressive form of nonalcoholic fatty liver disease. Several studies suggest that pentoxifylline (PTX) can improve the disease outcome. OBJECTIVES We aimed to compare the effect of pentoxifylline with placebo on liver aminotransferases and cytokines, including interleukin 6 (IL-6), tumor necrosis factor alpha (TNF-α), and interleukin 8 (IL...
متن کاملmetformin in nonalcoholic steatohepatitis: a randomized controlled trial
background nonalcoholic steatohepatitis (nash) is a common liver disease that can progress to cirrhosis or hepatocellular carcinoma. it is estimated that up to 3% of the iranian population have this condition. although the pathogenesis of nash is incompletely understood, there is significant evidence pointing to the importance of insulin resistance. metformin is an oral hypoglycemic agent known...
متن کاملMetformin in Nonalcoholic Steatohepatitis: A Randomized Controlled Trial
BACKGROUNDN onalcoholic steatohepatitis (NASH) is a common liver disease that can progress to cirrhosis or hepatocellular carcinoma. It is estimated that up to 3% of the Iranian population have this condition. Although the pathogenesis of NASH is incompletely understood, there is significant evidence pointing to the importance of insulin resistance. Metformin is an oral hypoglycemic agent known...
متن کاملA randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis.
The aim of this study was to evaluate cenicriviroc (CVC), a dual antagonist of CC chemokine receptor types 2 and 5, for treatment of nonalcoholic steatohepatitis (NASH) with liver fibrosis (LF). A randomized, double-blind, multinational phase 2b study enrolled subjects with NASH, a nonalcoholic fatty liver disease activity score (NAS) ≥4, and LF (stages 1-3, NASH Clinical Research Network) at ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Hepatology
سال: 2011
ISSN: 0270-9139
DOI: 10.1002/hep.24544